Objective: To systematically evaluate the clinical efficacy and safety of Yangxue Qingnao granules in treating chronic cerebral circulation insufficiency (CCCI). Method: The systematical evaluation method was adopted to search Chinese and foreign randomized controlled trails (RCTs) of Yangxue Qingnao granules in treating CCCI

screen out eligible studies and evaluate the quality of the included studies. Heterogeneity test

Meta-analysis

funnel plot analysis and sensitivity analysis were adopted in the statistics of relevant data. Result: The 12 RCTs were selected. The Meta-analysis indicated that the ratio between the combined RR of total effective rate and the 99% confidential interval (CI) was 1.23 (1.14

1.33). The combined MD of transcranial doppler(TCD) detected carotid artery

vertebral artery

basilar artery blood flows (99%CI) respectively were (2.29

13.94)

2.54 (0.21

4.87)

5.60 (2.35

8.66);PetoOR of the incidence rate of extrapyramidal symptoms and gastrointestinal reaction (99%CI) were 0.11 (0.01

1.77)

8.07 (0.77

84.94)

respectively. Conclusion: Meta-analysis shows that Yangxue Qingnao granules has the efficacy in increasing cerebral blood flow of patients with chronic brain and improving their cognitive function

but with uncertain risks in causing adverse reactions. Affected by such factors as lower quality of included studies

the systematic evaluation's conclusion is lowly reliable.